Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576431 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
A Phase 2 study of Solid Tumors Harboring NTRK Fusion, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
- 20
- Study locations
NCT02576431 is a Phase 2 study of Solid Tumors Harboring NTRK Fusion that has completed, run by Bayer. The registered enrollment target is 215 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02576431, a Phase 2 study of Solid Tumors Harboring NTRK Fusion, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
Conditions Studied
Interventions
- DRUG BAY2757556 (Larotrectinib, Vitrakvi)
Study Locations (20)
California
- Stanford Cancer Center Palo Alto - Palo Alto
- UCLA Health Santa Monica Cancer Care - Santa Monica
Massachusetts
- Mass General Cancer Center - Boston
- Dana-Farber Cancer Institute - Oncology Department - Boston
North Carolina
- UNC Hospitals - UNC Lineberger Comprehensive Cancer Center - Chapel Hill
- Wake Forest Baptist Health - Winston-Salem
Pennsylvania
- Sidney Kimmel Cancer Center - Jefferson Health - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Ciudad Auton. de Buenos Aires
- Hospital Alemán - Buenos Aires
- Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno" - Buenos Aires
Florida
- Memorial Cancer Institute at West - Pembroke Pines
Illinois
- The University of Chicago Medical Center - Hyde Park - Hematology & Oncology - Chicago
New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2025-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576431
The ClinicalTrials.gov registry entry for NCT02576431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors Harboring NTRK Fusion appearing as the primary indexed condition, and to 1 intervention - of which BAY2757556 (Larotrectinib, Vitrakvi) is the first listed.
NCT02576431 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02576431 about?
NCT02576431 is a clinical study titled "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors". This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used t...
What is the current status of trial NCT02576431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2015-09-30. Estimated completion is 2025-09-29.
What conditions does trial NCT02576431 study?
This clinical trial studies the following conditions: Solid Tumors Harboring NTRK Fusion.
What interventions are being tested in trial NCT02576431?
The interventions under investigation include: BAY2757556 (Larotrectinib, Vitrakvi) (DRUG).
Who is sponsoring clinical trial NCT02576431?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576431 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors Harboring NTRK Fusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
ACTIVE NOT RECRUITING · Phase 1
-
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.